We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-17.49%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.12B
AUM Growth
-$643M
Cap. Flow
-$73.8M
Cap. Flow %
-3.48%
Top 10 Hldgs %
32.59%
Holding
150
New
6
Increased
39
Reduced
39
Closed
17

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$41.3M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$26.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.7M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$12.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$30.7M
2
MOH icon
Molina Healthcare
MOH
+$26.6M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$17.3M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15.6M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.36%
2 Consumer Staples 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
26
DELISTED
Alexion Pharmaceuticals
ALXN
$23.6M 1.11%
242,500
-57,500
-19% -$6.8M
ACHC icon
27
Acadia Healthcare
ACHC
$2.94B
$23.2M 1.09%
900,750
+200,750
+29% +$6.95M
ALGN icon
28
Align Technology
ALGN
$12.3B
$22M 1.04%
105,000
+37,500
+56% +$9.47M
TMO icon
29
Thermo Fisher Scientific
TMO
$220B
$21.5M 1.01%
96,000
– –
ALLK
30
DELISTED
Allakos
ALLK
$21.1M 1%
404,000
-1,000
-0.2% -$50.1K
ONCE
31
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$21M 0.99%
537,500
– –
IDXX icon
32
Idexx Laboratories
IDXX
$46.2B
$20.6M 0.97%
110,500
+27,000
+32% +$5.54M
BAX icon
33
Baxter International
BAX
$14.2B
$19.8M 0.93%
300,700
+3,700
+1% +$249K
INCY icon
34
Incyte
INCY
$24.4B
$19.7M 0.93%
310,000
-42,100
-12% -$2.73M
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$2.55B
$18.5M 0.87%
425,000
+225,000
+113% +$12.3M
PRAH
36
DELISTED
PRA Health Sciences, Inc.
PRAH
$18.4M 0.87%
200,000
-88,247
-31% -$8.93M
RDUS
37
DELISTED
Radius Health, Inc.
RDUS
$18.1M 0.86%
1,100,000
-167,500
-13% -$2.82M
ARGX icon
38
argenx
ARGX
$54.1B
$17.1M 0.81%
178,000
+13,000
+8% +$1.16M
LKFT
39
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$16.3M 0.77%
177,500
– –
WST icon
40
West Pharmaceutical
WST
$24.9B
$15.7M 0.74%
160,000
– –
NVTA
41
DELISTED
Invitae Corporation
NVTA
$15.5M 0.73%
1,400,000
– –
ASND icon
42
Ascendis Pharma A/S
ASND
$16.8B
$15.3M 0.72%
243,500
– –
ALDR
43
DELISTED
Alder Biopharmaceuticals
ALDR
$15.1M 0.71%
1,475,000
-157,500
-10% -$2.02M
BIIB icon
44
Biogen
BIIB
$30.7B
$15M 0.71%
50,000
– –
INGN icon
45
Inogen
INGN
$164M
$14.5M 0.69%
117,000
-9,000
-7% -$1.48M
OBSV
46
DELISTED
ObsEva SA Ordinary Shares
OBSV
$14.2M 0.67%
1,120,000
– –
KYNB
47
Kyntra Bio
KYNB
$29.4M
$14.2M 0.67%
12,240
– –
ALNY icon
48
Alnylam Pharmaceuticals
ALNY
$29.3B
$14.1M 0.67%
194,000
-2,500
-1% -$192K
TBPH icon
49
Theravance Biopharma
TBPH
$877M
$14.1M 0.66%
550,000
– –
MDCO
50
DELISTED
Medicines Co
MDCO
$13.9M 0.66%
726,900
+36,900
+5% +$858K
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Rock Springs Capital Management held 150 positions worth $2.12B, down 23% from $2.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $73.8M in Q4 2018, closing 17 positions and reducing 39 holdings. Its most notable exit was AbbVie, an estimated $30.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 90% a quarter earlier, followed by Consumer Staples.

Against the trend, Rock Springs Capital Management opened a new position in Seagen Inc. Common Stock worth $11.5M.

  • Rock Springs Capital Management's largest Q4 2018 buy was Seagen Inc. Common Stock: 202,500 shares worth $11.5M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q4 2018, an estimated $41.3M increase.
  • Rock Springs Capital Management's biggest Q4 2018 reduction was Molina Healthcare, cutting an estimated $26.6M.
  • Rock Springs Capital Management fully exited AbbVie in Q4 2018, selling an estimated $30.7M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $2.12B portfolio in Q4 2018.
  • Rock Springs Capital Management opened 6 new positions and closed 17 in Q4 2018.
  • Rock Springs Capital Management's portfolio value fell 23% quarter-over-quarter to $2.12B.

Based on Rock Springs Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.